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Abstract 26 
Bowman-Birk inhibitors (BBI) from soybean and related proteins are naturally occurring 27 
protease inhibitors with potential health promoting properties within the gastrointestinal tract. In 28 
this work, we have investigated the effects of soybean BBI proteins on HT29 colon 29 
adenocarcinoma cells, compared with non-malignant colonic fibroblast CCD-18Co cells. Two 30 
major soybean isoinhibitors, IBB1 and IBBD2, showing considerable amino acid sequence 31 
divergence within and between their inhibitory domains, were purified in order to examine their 32 
functional properties, including their individual effects on the proliferation of HT29 colon cancer 33 
cells. IBB1 inhibited both trypsin and chymotrypsin whereas IBBD2 inhibited trypsin only. 34 
Despite showing significant differences in their enzyme inhibitory properties, the median 35 
inhibitory concentration (IC50) values determined for IBB1 and IBBD2 on HT29 cell growth were 36 
not significantly different (39.9 ± 2.3 and 48.3 ± 3.5 µM, respectively). The cell cycle distribution 37 
pattern of HT29 colon cancer cells was affected by BBI treatment in a dose-dependent manner, 38 
will cells becoming blocked in the G0-G1 phase. Chemically inactive soybean BBI had a weak but 39 
non-significant effect on the proliferation of HT29 cells. The anti-proliferative properties of BBI 40 
isoinhibitors from soybean reveal that both trypsin- and chymotrypsin-like proteases involved in 41 
carcinogenesis should be considered as potential targets of BBI-like proteins. 42 
  43 
 44 
 45 
 46 
 47 
 48 
 49 
 50 
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1. Introduction 51 
 52 
Colorectal cancer (CRC) is a complex disease that reflects a combination of lifestyle factors and 53 
multi-step genetic alterations. It has become one of the major causes of morbidity and mortality in 54 
western countries; therefore, much attention has been focused on preventive strategies. One of the 55 
most effective means of preventing or reducing colon cancer risk is either directly or indirectly 56 
linked to appropriate diet and/or nutritional manipulation [1, 2]. The fact that certain dietary 57 
constituents can exert cancer chemopreventive properties has major public health implications and 58 
their widespread, long-term use should be promoted in populations at normal risk, based on 59 
understanding the scientific basis of their effects. Naturally occurring protease inhibitors (PI) of 60 
the Bowman-Birk family, a major PI class in legumes such as soybean (Glycine max), pea (Pisum 61 
sativum) and chickpea (Cicer arietinum), have been linked to a possible protective effect against 62 
inflammation and cancer development within the gastrointestinal tract (GIT) [3-5]. Bowman-Birk 63 
inhibitors (BBI) have been shown to be structurally and functionally resistant to the challenges of 64 
the GIT in vivo. BBI from chickpea seeds can resist both acidic conditions and the action of 65 
proteolytic enzymes, and transit through the stomach and small intestine without major 66 
degradation, permitting significant amounts to reach the larg  intestine in active form [6]. Further 67 
studies have demonstrated that the protease inhibitory activities of soybean BBI are unaffected by 68 
the metabolic/proteolytic activities of faecal microbiota, thereby retaining activity potentially 69 
linked to colorectal cancer preventive properties [7]. Such extraordinary stability seems to be 70 
linked to the presence of a highly conserved array of intra-chain disulphide bridges that stabilise a 71 
symmetrical structure of two tricyclic domains, each containing an independent serine protease 72 
binding site [8-10]. 73 
Several in vitro and in vivo studies have demonstrated that BBI proteins may exert a 74 
protective and/or suppressive effect in CRC development and associated inflammatory disorders. 75 
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A soybean BBI concentrate (BBIC), an extract enriched in BBI, exerted a protective effect in 76 
dimethylhydrazine (DMH)-treated animals, reducing the incidence and frequency of colon tumours 77 
in mice [11,12] and rats [3]. In these studies, no adverse side effects of BBIC were documented for 78 
either animal growth or organ physiology. BBI-like proteins from field beans (Dolichos lablab) 79 
have been shown to be biologically active in suppressing benzopyrene-induced forestomach 80 
carcinogenesis in mice, following oral treatment [13]. The effectiveness of BBI in the reduction 81 
and/or suppression of inflammatory processes within the GIT has been reported also. Addition of 82 
BBIC to the diet of mice resulted in a suppression of inflammation in the dextran sulphate sodium 83 
model of ulcerative colitis [14] and such a beneficial effect could be related to the ability of BBI to 84 
inhibit serine proteases, such as leukocyte elastase, cathepsin G and mast cell chymase, released 85 
from inflammation-mediating cells.  86 
 In legume seeds, BBI are proteins with two inhibitory loops that can independently inhibit 87 
two enzyme molecules. These may be the same (trypsin-like) or different (trypsin- and 88 
chymotrypsin-like) enzymes [15, 16]; additionally, some BBI can inhibit leukocyte elastase [4]. 89 
Because of an apparent association of the chymotrypsin inhibitory binding site with anti-90 
carcinogenic properties [17], it has been hypothesised that chymotrypsin-like proteases are likely 91 
to be involved in carcinogenesis [18]. Recently, we have demonstrated the effect of sequence 92 
variation within the chymotrypsin inhibitory domain of BBI from pea on their functional properties 93 
[19] as well as on their ability to inhibit the growth of human colorectal adenocarcinoma cells [20]. 94 
The relevance of the trypsin inhibitory domains of BBI on health benefits has not been examined 95 
specifically, and trypsin-like proteases involved in carcinogenesis should be investigated as 96 
potential targets of BBI-like proteins [4]. In this work, we demonstrate that soybean BBI, 97 
consisting of multiple isoinhibitors, inhibited the in vitro cell growth of HT29 colon 98 
adenocarcinoma cells as a consequence of their intrinsic ability to inhibit the proteolytic activities 99 
of serine proteases, where denatured BBI showed no such biological effect. We demonstrate that 100 
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the cell cycle distribution pattern of HT29 colon cancer cells is affected by BBI treatment. In 101 
contrast, the growth of normal colonic fibroblast CCD-18Co control cells was unaffected by 102 
soybean BBI proteins. Two major soybean isoinhibitors, IBB1 and IBBD2, showing considerable 103 
amino acid sequence divergence within and between their inhibitory domains, were purified in 104 
order to evaluate their individual effects on the proliferation of HT29 colon cancer cells. Strikingly, 105 
the effective and positive contribution of the trypsin inhibitory domain to the anti-proliferative 106 
properties of BBI was revealed by evaluation of the double-headed trypsin inhibitor IBBD2. These 107 
data further advance our knowledge and understanding of the relevance of sequence variation 108 
within the inhibitory domains of BBI in relation to their colorectal anti-proliferative properties. 109 
 110 
2. Materials and methods 111 
 112 
2.1 Materials. Bowman-Birk inhibitors (BBI) from soybean (T9777), trypsin (type III) and α-113 
chymotrypsin (type VII) from bovine pancreas, N-α-benzoyl-DL-arginine-p-nitroanilide (BAPNA), 114 
N-benzoyl-L-tyrosine ethyl ester (BTEE), DMEM, neutral red (NR) and additional cell culture-115 
grade chemicals were obtained from Sigma (Alcobendas, Spain). The human colorectal 116 
adenocarcinoma HT29 and the normal colon fibroblastic CCD-18Co cell lines were supplied by 117 
the Cell Bank of the Scientific Instrumentation Centre at the University of Granada (CIC-UGR, 118 
Granada, Spain). Culture flasks and flat bottom ninety-six well microtitre plates were purchased 119 
from Corning Costar (Cambridge, MA, USA) and Nunc (Wiesbaden, Germany), respectively. All 120 
other chemicals were of analytical grade.  121 
 122 
2.2 Measurement of protease inhibitory activities. BBI from soybean and their major 123 
constituent isoinhibitors, IBB1 and IBBD2 (see section 2.4), were assessed for trypsin (TIA) and 124 
chymotrypsin inhibitory activity (CIA). TIA was measured using a modified small-scale 125 
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 6 
quantitative assay, with BAPNA as specific substrate, and using 50 mM Tris, pH 7.5 as enzyme 126 
assay buffer.  One trypsin inhibitor unit (TIU) was defined as that which gives a reduction in 127 
absorbance at 410 nm of 0.01, relative to trypsin control reactions, in a defined assay volume of 10 128 
mL [21]. CIA was measured using BTEE as specific substrate. One chymotrypsin inhibitor unit 129 
(CIU) was defined as that which gives a reduction in absorbance at 256 nm of 0.01, relative to 130 
chymotrypsin control reactions, in a defined assay volume of 10 mL [19]. Specific TIA and CIA of 131 
major soybean BBI isoinhibitors, expressed as inhibitor units (IU) per mg of protein, were 132 
calculated. The inhibition constants (Ki) of purified isoinhibitors for trypsin (at pH 7.5) and 133 
chymotrypsin (at pH 7.8), were determined from dose-response curves by competitive assays, 134 
using the chromogenic substrates BAPNA and BTEE, respectively [19]. The reactions were 135 
initiated by adding trypsin (108 nM) or chymotrypsin (28 nM) with the respective substrate 136 
concentrations determined by Km measurements. The concentration of inhibitor required to achieve 137 
a half-maximal degree of inhibition (IC50) was determined for each protease, using the GraFit 138 
software (GraFit Version 5, Erithacus Software Ltd., Horley, UK). Ki were calculated from IC50 139 
values using the tight-binding equations for competitive inhibitors as previously described by 140 
Copeland et al. [22]. The trypsin and chymotrypsin inhibitory properties of soybean BBI were 141 
analyzed furthermore on 4-16 % zymogram blue casein gels (Invitrogen, Barcelona, Spain).  142 
Unfractionated BBI or individual isoinhibitors (16 or 32 µg, respectively) were loaded on 143 
zymogram gels for the detection of trypsin or chymotrypsin inhibitory activity. Following 144 
electrophoresis, and according to the manufacturer´s instructions, gels were treated with zymogram 145 
renaturating buffer (Invitrogen) for 30 min at room temperature, equilibrated with zymogram 146 
developing buffer (Invitrogen), incubated with 10 mL of trypsin or chymotrypsin solution (0.2 147 
mg/mL of zymogram developing buffer) at 37 ºC for 1.5 h, and washed with distilled water before 148 
the addition of acetic acid to stop the enzymatic reaction. Areas of the gels that remained blue 149 
indicated where trypsin or chymotrypsin had been inhibited. 150 
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2.3 Chemical inactivation of soybean BBI. To abolish the trypsin and chymotrypsin inhibitory 151 
activities of soybean BBI, alkylation of the sulfhydryl groups was carried out. Ten milligrams of 152 
soybean BBI were reduced with DTT, and alkylated with 400 µL of 0.25 M iodoacetamide (IAA) 153 
for 15 min at 50 ºC under dark conditions. In order to remove residual DTT and IAA, samples 154 
were dialyzed extensively against distilled water and freeze-dried. To confirm their inactivation, 155 
soybean BBI were tested for loss of activity against trypsin and chymotrypsin enzymes, and were 156 
stored at -20 °C.    157 
 158 
2.4 Purification of major soybean BBI isoinhibitors. The major BBI isoinhibitors, IBB1 and 159 
IBBD2, were purified from soybean BBI, using a reverse-phase HPLC column (Ace® 300Å, C4, 160 
250 x 4.6mm I.D., 5 µm particle size, Advanced Chromatography Technologies, Aberdeen, 161 
Scotland) attached to a Beckman System Gold HPLC equipped with System Gold Software data 162 
acquisition system version 711 (Beckman Instruments, Fullerton, CA, USA). Soybean BBI were 163 
dissolved in solvent A [0.1% (v/v) TFA in MilliQ water] at a concentration of 5mg/mL. The 164 
elution was performed at room temperature using a linear gradient by increasing the concentration 165 
of solvent B [0.1% (v/v) TFA in acetonitrile/MilliQ water (90:10, v/v)] from 15 to 35 % (v/v) in 20 166 
min. The flow rate and volume injection were 1 mL/min and 100 µL, respectively, and the 167 
absorbance was recorded at 214 nm using a Beckman 166 UV detector. Eluted proteins were 168 
collected manually, concentrated in a vacuum centrifuge (SpeedVac Concentrator A 160, Savant 169 
Instruments, Farmingdale, NY 11735, USA) and stored at -20 °C, before further analyses. The 170 
purity of the BBI isoinhibitors was determined by IEF; 10 µg of each isoinhibitor were dissolved 171 
in Novex® IEF pH 3-7 sample buffer and loaded on Novex® gels in the pH range 3–7, according 172 
to the manufacturer´s protocol (Invitrogen). Gels were stained using the Colloidal Blue staining kit 173 
(Invitrogen).  174 
 175 
Page 8 of 36
Wiley-VCH
Molecular Nutrition and Food Research
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 8 
2.5 Peptide mass fingerprinting of BBI isoinhibitors. Proteins (10 µg) were dissolved in 176 
NuPAGE® LDS sample buffer (Invitrogen) and separated by electrophoresis on Novex 12 % Bis-177 
Tris pre-cast gels using NuPAGE® MES as running buffer (Invitrogen). Immediately before use, 178 
samples were reduced with DTT and NuPAGE antioxidant added to the upper buffer chamber to 179 
prevent reduced proteins from re-oxidation during electrophoresis. Bands corresponding to 180 
individual isoinhibitors were excised from Colloidal Blue (Invitrogen)-stained gels and subjected 181 
to in-gel trypsin digestion. Peptide fragments from digested proteins were desalted and 182 
concentrated using C-18 ZipTip columns (Millipore, Madrid, Spain) and then directly loaded onto 183 
the MALDI plate, using α-cyanohydroxycinnamic acid as the matrix for MALDI-MS analysis. MS 184 
spectra were obtained automatically in a 4700 Proteomics Analyzer (Applied Biosystems, Foster 185 
City, CA, USA) operating in reflectron mode with delayed extraction. Peptide mass data were used 186 
for protein identification against the MSDB sequence database (www.matrixscience.com). 187 
 188 
2.6 Cell viability assays. Human colorectal adenocarcinoma HT29 and normal colon fibroblastic 189 
CCD-18Co cells were maintained by serial passage in 75 cm2 plastic culture flasks. HT29 cells 190 
were cultured in DMEM, supplemented with fetal bovine serum (5 %), 2 mM glutamine and 1 % 191 
antibiotic-antimicotic solution (Sigma, A5955). In the case of CCD-18Co fibroblastic cells, media 192 
were additionally supplemented with 1 % non-essential amino acids solution (Sigma, M7145). 193 
Optimal assay conditions for colonic cells were reported previously [20]. Briefly, ninety-six well 194 
microtitre plates were inoculated at a density of 2,000 cells per well in 200 µL of growth media, 195 
and were incubated under 5 % CO2 in humidified air for 24 h to allow the cells to adhere to the 196 
wells. Soybean BBI, native or chemically inactivated (see section 2.3), or the purified major 197 
isoforms (IBB1 and IBBD2, individually or in combination in order to investigate a potential 198 
synergistic effect) were dissolved in growth media at a range of concentrations (0-125 µM) and 199 
added to the cells under sterile conditions. Control cells received no BBI. At the end of the growth 200 
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 9 
period (24-96 h), the viability of HT29 and CCD-Co18 cells was assessed by the NR (3-amino-7-201 
dimethylamino-2-methyl-phenazine hydrochoride) cytotoxicity assay, based on the ability of 202 
viable uninjured cells to incorporate and actively bind NR, a supravital dye, into lysosomes. Cells 203 
were stained with NR solution (2 h at 37 °C), followed by cell fixation (0.5 % formaldehyde, 204 
0.1 % CaCl2 for 30 sec) at room temperature. Plates were washed by two brief immersions in PBS 205 
and the dye extracted from the viable cells using an acidified ethanol solution (50 % ethanol, 1 % 206 
acetic acid) at 4 ºC overnight. The absorbance of the solubilized dye was quantified at 550 nm 207 
using a BioRad Model 550 microplate reader (BioRad, CA, USA). Cell viability data, expressed as 208 
a percentage of the values determined for control cells grown in the absence of BBI, were obtained 209 
from at least three independent experiments (with n ≥ 4 replicates  per experiment). The 210 
concentration of BBI and individual isoinhibitors that reduced cell viability by 50 % (IC50), as 211 
compared with untreated controls, was calculated by non-linear regression fit using the GraFit 212 
software. Statistical analysis was performed using Statgraphics Plus 5.1 software (StatPoint Inc., 213 
Herndon, VA, USA). Bonferroni´s test was used to compare means and statistical significance was 214 
set at P < 0.05. 215 
 216 
2.7 Cell cycle distribution analysis. To assess whether or not the effects of soybean BBI on cell 217 
growth are mediated via alterations in the cell cycle, cell cycle distribution patterns were analysed. 218 
HT29 cells were seeded at a density of 105 cells per mL of growth media and incubated, under 5 % 219 
CO2 in humidified air, for 24 h to allow the cells to adhere to 25 cm2 cell culture flasks. Soybean 220 
BBI were dissolved in growth media at concentrations of 31 or 62 µM and immediately added, 221 
under sterile conditions, to the HT29 colon cancer cells. Control samples received no BBI. After 222 
24 h exposure, cells were harvested by centrifugation, washed with cold PBS (200 µL) and fixed in 223 
ice-cold 70 % ethanol (2 mL) for 30 min at 4 ºC, before addition of 100 µL RNase (1 mg/mL) and 224 
100µL of propidium iodide (400 µg/mL).  After incubation for 30 min at 37 ºC in the dark, the 225 
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 10 
fluorescence of stained cells was analysed by fluorescence activated cell sorting flow cytometry 226 
(Becton Dickinson Immunocytometry system, San Jose, CA, USA). Data acquisition and analysis 227 
were performed using ModFit LT (Verity Software House Topsham, ME, USA) and CellQuest 228 
software (Becton Dickinson), respectively.  229 
 230 
3. Results 231 
 232 
3.1 Isolation and functional characterization of soybean BBI isoinhibitors. Analysis of 233 
commercial preparations of soybean BBI by SDS-PAGE showed a single band of appropriate 234 
molecular mass (8 kDa) (Figure 1a). Nevertheless, IEF analysis demonstrated the presence of up 235 
to 11 components within the pI range 4.1-5.2, with two major peptides showing pI values of 4.7 236 
and 4.1, respectively (Figure 1b). Comparison of amino acid sequences of soybean BBI from the 237 
UniProt KB-Swiss Prot database predicted an overall difference in charge, reflecting differences in 238 
the content of both negatively and positively charged amino acids. In addition, soybean BBI 239 
differed in their predicted overall mass and hydrophobicity, features that are likely to contribute to 240 
their separation by RP-HPLC. In agreement with this, soybean BBI were resolved as two major 241 
chromatographic peaks by RP-HPLC (Figure 2a). These peaks, representing approximately 33 % 242 
and 41 % of the total BBI content as estimated from their relative peak areas, were collected 243 
manually and shown to correspond to the main isoelectrofocusing bands present in the starting 244 
material (Figure 2b). Additional minor chromatographic peaks were also detected as either 245 
separate or unresolved peaks (Figure 2a), that were not collected to maximize the purity of the 246 
major isoinhibitors. In order to identify the purified isoinhibitors, in-gel tryptic digestion of excised 247 
bands was performed, followed by separation of the peptides generated and mass spectrometric-248 
based analysis. A search of peptide mass data against the MS protein sequence database (MSDB) 249 
enabled the unambiguous identification of both BBI isoinhibitors. The purified proteins, 250 
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corresponding to the chromatographic peaks 1 and 2 (see Figure 2a), were identified by mass 251 
peptide fingerprinting as Bowman-Birk type proteinase inhibitor D-II (Swiss-Prot entry: 252 
IBBD2_SOYBN) and Bowman-Birk proteinase inhibitor (Swiss-Prot entry: IBB1_SOYBN), 253 
showing 96 and 56 % sequence coverage, respectively (Table 1). An amino acid sequence 254 
comparison of IBBD2 and IBB1 proteins is shown in Table 2, where the peptide sequences that 255 
contributed to protein identification by mass spectrometry are indicated. The 14 cysteine residues 256 
are in the conserved positions, as previously described for other BBI proteins [10]. Following the 257 
nomenclature of Schechter and Berger [23], IBBD2 showed two almost identical inhibitory 258 
domains, except for positions P2´ and P4´. The residue Arg was present at position P1 in both 259 
inhibitory domains, conferring specificity for inhibition of trypsin-like proteases. In the case of 260 
IBB1, variation at several positions within the two inhibitory domains was observed, and the 261 
presence of Lys or Leu in position P1 confers a different specificity for inhibition of trypsin- or 262 
chymotrypsin-like proteases, respectively.  263 
The specific TIA and CIA of the starting material (commercially available BBI, Figure 1) 264 
were 3075 ± 59 and 2190 ± 27 units per mg of protein, respectively. Following reduction and 265 
alkylation of disulphide bonds, these activities were reduced by greater than 95 % (data not shown). 266 
Of the two purified BBI isoinhibitors, IBBD2 showed TIA but no detectable CIA, whereas IBB1 267 
showed both TIA and CIA (Table 3). IBBD2 showed a higher specific TIA than IBB1 (3710 ± 268 
257 and 2572 ± 122 TIU per mg of protein, respectively, Table 3) in agreement with the nature of 269 
the two P1´ residues. IBB1 showed a high specific CIA (5691 ± 365 CIU per mg of protein), in 270 
contrast to IBBD2, where CIA was not detected. These significant differences in specific 271 
inhibitory activities are likely to reflect the variation in the amino acid sequences of the inhibitory 272 
domains (Table 3) that play an essential role in determining specificity and potency [4]. Based on 273 
IC50 and Ki calculations, IBBD2 was demonstrated to be a stronger inhibitor of trypsin (Ki of 14.8 274 
nM) when compared with IBB1 (Ki of 29.8 nM), where the latter was a potent inhibitor of 275 
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chymotrypsin (Ki of 3.3 nM) (Table 3). Such values fall within the nanomolar range reported 276 
previously for various members of the BBI family, including those from pea [19, 24], lentil (Lens 277 
culinaris) [25] and lupin (Lupinus albus) [26]. As shown in Figure 3, zymography under non-278 
denaturing conditions allowed the separation of soybean BBI isoinhibitors as well as the detection 279 
of specific inhibitory activities against the digestive enzymes trypsin and chymotrypsin. In good 280 
agreement with the kinetic data (Table 3), IBBD2 showed inhibition against trypsin only (Figure 281 
3, track 3), whereas IBB1 clearly inhibited both trypsin and chymotrypsin enzymes (Figure 3, 282 
track 4). Chemically inactivated BBI failed to inhibit the activity of either enzyme (Figure 3, track 283 
1) in contrast to unfractionated proteins showing inhibition of both enzymes (Figure 3, track 2).  284 
 285 
3.2 Effect of soybean BBI on the proliferation of human colon cells. The effects of BBI on the 286 
growth of human colon adenocarcinoma HT29 cells were determined by comparing the growth of 287 
cells cultured in the absence or presence of BBI (0-125 µM), monitored by the cytotoxic NR cell 288 
assay. At concentrations greater than 31 µM, soybean BBI inhibited the in vitro cell growth of 289 
HT29 human colon adenocarcinoma cells in a concentration-dependent manner (Figure 4). The 290 
growth of HT29 cells was much less significantly reduced when treated with BBI that had been 291 
chemically inactivated (Figure 5a). Our results clearly suggest that the antiproliferative effects of 292 
soybean BBI on HT29 cells are associated with their intrinsic ability to inhibit serine proteases. In 293 
contrast, the growth of colonic fibroblast CCD-18Co cells was unaffected by soybean BBI, in 294 
either active or inactivated form, even at the highest concentration tested (125 µM) (Figure 5b). 295 
Given the contrasting specific activities (Table 3) of the two purified isoinhibitors, IBBD2 296 
and IBB1, the effects of these two on the growth of HT29 cells were examined. A statistically 297 
significant (P<0.05) and dose-dependent decrease of the growth of HT29 colon cells was observed 298 
after treatment with either IBBD2 or IBB1 (Figure 6). At 31 and 62 µM, a larger effect was 299 
observed for IBBD2, compared with IBB1. Despite showing significant differences in their 300 
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functional properties (Table 3), the median inhibitory concentration (IC50) values for the 301 
individual isoinhibitors, IBBD2 and IBB1, on HT29 cell growth were not significantly different 302 
(39.9 ± 2.3 and 48.3 ± 3.5 µM, respectively). These data were in agreement with the IC50 values 303 
obtained for the commercial BBI preparation (Figure 1) (46 ± 2.4 µM), suggesting a non-304 
synergistic effect of individual inhibitors. This was confirmed when the two isoinhibitors were 305 
used individually or in combination at a final concentration of 62 µM (data not shown).  306 
To investigate whether the effects of soybean BBI on cell growth were due to cell cycle 307 
arrest, the cell cycle distribution pattern of HT29 cells was evaluated in the presence or absence of 308 
soybean BBI, using different concentrations of BBI (31 and 62 µM). After 24 h exposure to 309 
soybean BBI, the accumulation of HT29 cells in the G0-G1 stage was revealed, compared with 310 
control cells grown without BBI, and this effect was shown to be dose-dependent (Figure 7). The 311 
histogram of DNA content in HT29 cells treated with 62 µM soybean BBI showed a significant 312 
increase in the G0-G1 peak from 62.7 ± 0.2 % to 89.1 ±1.6  %, whereas the cell population in G2-313 
M and S stage decreased significantly from 28.2 ± 1.2 % to 4.3 ± 1 % and 9.2 ± 1 % to 6.6 ± 0.6 %, 314 
respectively, as compared to untreated cells.   315 
 316 
4. Discussion  317 
 318 
The use of naturally-occurring compounds as chemopreventive agents in order to block, 319 
inhibit, reverse or retard the process of carcinogenesis is a novel and promising approach to 320 
prevent cancer [27]. In CRC, one of the leading causes of cancer-related mortality in western 321 
countries, nutritional intervention offers great potential to delay or prevent the development of 322 
malignant processes; such an interventional strategy might result in a positive impact on the 323 
incidence of disease and mortality [28]. In this context, soybean BBI and related proteins have 324 
recently emerged as highly promising chemotherapeutic compounds within the GIT [3-5]. The 325 
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effectiveness of soybean BBI in preventing or suppressing cancer development in DMH-induced 326 
colon tumours has been demonstrated in rodents [3, 29]. In this work, we demonstrate that soybean 327 
BBI exert an anti-proliferative effect on HT29 colon adenocarcinoma cells in a dose-dependent 328 
manner, whereas non-malignant colonic fibroblast CCD-18Co cells were unaffected.  Interestingly, 329 
chemically inactivated BBI had a weak but non-significant effect on the proliferation of HT29 330 
colon cancer cells; such a weak effect could be a result of the residual inhibitory activity (≤5 % of 331 
the original activity). These data clearly suggest that the anti-proliferative activity of BBI on HT29 332 
cells is mediated via protease inhibition. These findings reveal the need to evaluate the amounts of 333 
active BBI present in soybean foods that could potentially exert a protective function in the large 334 
intestine. Recent studies have demonstrated the presence of BBI in a large number of commercial 335 
soybean foods [30]. In soy milk samples, BBI were present at between 7.2 and 55 mg per 100 mL 336 
of product; in the case of other soybean foods like soybean cake and bean curd, up to 19.2 mg of 337 
BBI per 100 g of product was found. The reported amounts seem to be physiologically relevant in 338 
order to exert anticancer effects in humans [31]; however, these data are based on immunoreactive 339 
forms of BBI that could be functionally inactive. It is worth noting that BBI are extremely resistant 340 
to denaturation by heat treatment [32, 33]. The chemical denaturation that was performed in this 341 
study is a harsh treatment that is quite removed from any process performed during food 342 
manufacture, but yet the former did not completely abolish activity. Understanding the 343 
relationships between protease inhibitory activities of BBI, specifically linked to their 344 
chemopreventive properties, and food manufacturing would provide a valuable insight to the likely 345 
beneficial effects of BBI-containing foods on gastrointestinal health.   346 
Previous studies have suggested an involvement of the chymotrypsin binding site of BBI in 347 
the anti-carcinogenic properties of these proteins, leading to the hypothesis that chymotrypsin–like 348 
proteases might play a relevant role in carcinogenesis [18, 34]. Yavelow et al. [17] reported that an 349 
enzymatically modified BBI from soybean having chymotrypsin inhibitory activity only was still 350 
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fully effective as an inhibitor of radiation-induced transformation in vitro. We have demonstrated 351 
previously the effect of sequence variation within the chymotrypsin inhibitory site, on the anti-352 
proliferative properties of BBI from pea [20]. In the current work, we show that both trypsin and 353 
chymotrypsin inhibitory activities of BBI proteins are likely to be involved in the anti-proliferative 354 
properties of BBI on colon cancer cells. A purified soybean isoinhibitor, IBBD2, having trypsin 355 
inhibitory activity only, exerted a significant inhibitory effect on the growth of HT29 cells. To our 356 
knowledge, data regarding the positive contribution of the trypsin inhibitory domain of BBI on 357 
their anti-proliferative properties have not been reported previously. Our results suggest clearly 358 
that trypsin-like proteases involved in carcinogenesis should be considered also as potential targets 359 
of BBI and related proteins.  360 
The homeostatic control between proteolytic enzymes and their cognate inhibitors plays a 361 
pivotal role in a number of physiological as well as pathological processes, including cancer and 362 
inflammatory disorders. An understanding of the role played by proteases in the biological 363 
processes associated with disease offers novel opportunities for therapeutic intervention [35]. 364 
Several serine proteases have been linked to tumour cell invasion and metastasis, and more 365 
recently, to angiogenesis and tumour growth [36, 37]. One such candidate is matriptase (MT-SP1), 366 
an epithelial-derived type II transmembrane serine protease, which exhibits trypsin-like protease 367 
activity and has been described in a variety of epithelial colon cancer cell lines [38]. Recent studies 368 
support the hypothesis that MT-SP1 acts as an upstream activator in metastasis and cancer 369 
invasion through the selective degradation of various elements of the cell-surrounding extracellular 370 
matrix and its inhibition could potentially modulate tumorigenesis and metastasis in vivo [39]. 371 
Although the ability of soybean BBI to inhibit the trypsin-like activity of MT-SP1 has been 372 
demonstrated [40], the clinical relevance of such inhibition has not been proven yet. Chymase, a 373 
key mediator in inflammatory cell signalling pathways, is a chymotrypsin-like serine protease 374 
which is stored primarily in mast cell granules and released upon degranulation, and has been 375 
Page 16 of 36
Wiley-VCH
Molecular Nutrition and Food Research
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 16 
reported to be susceptible to inhibition by soybean BBI [18]. It has also been suggested that BBI 376 
internalization by epithelial cells could facilitate the inhibition of intracellular target proteases 377 
associated with the transformation of normal to malignant cells [12]. Proteasomes are involved in 378 
control of the cell cycle by proteolytic degradation of several cell cycle regulatory proteins such as 379 
cyclins and cyclin-dependent kinases and thus represent a promising target structure for early 380 
anticancer strategies in combination with cytotoxic drugs [41]. Recently, it has been demonstrated 381 
that soybean BBI can inhibit in vitro and in vivo the proteasomal chymotrypsin-like activity in 382 
MCF-7 breast cancer cells, accompanied by down-regulation of cyclin D1 and cyclin E [42]; these 383 
recent findings suggest a novel mechanism for BBI in controlling cell proliferation processes and 384 
cell death. Elucidation of the mechanism(s) by which these dietary proteins can block cell cycle 385 
progression and exert antiproliferative activity will provide insights into the effect of BBI and 386 
related proteins as chemopreventive agents, and support the characterisation of variants as 387 
described in this work.  In combination, these data contribute to the development of new strategies 388 
for inhibitor design in cancer prevention programmes and potentially for further medical 389 
applications.     390 
 391 
Acknowledgements 392 
This work was carried out with the financial support of grants AGR2006-00706 and AGL 2007-393 
60007/ALI from Junta de Andalucía and Spanish CICYT, respectively. Alfonso Clemente 394 
acknowledges receipt of a Ramon and Cajal contract.  The JIC is supported by competitive grants 395 
from the Biotechnology and Biological Sciences Research Council (BBSRC, U.K.), as well as 396 
from the Department for Environment Food and Rural Affairs (Defra, U.K.). We are very grateful 397 
to Dr S. Ogueta from the Proteomics Facility of University of Cordoba for carrying out peptide 398 
mass fingerprinting.  Thanks are due to Dr. J. Lazuen from the Scientific Instrumentation Centre at 399 
Page 17 of 36
Wiley-VCH
Molecular Nutrition and Food Research
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 17 
the University of Granada (CIC-UGR, Granada, Spain) for carrying out the flow cytometry 400 
analysis on HT29 and CCD-18Co cells. The study is not subject to any conflicts of interest.  401 
 402 
 403 
5. References 404 
[1] Cummings, J.-H., Bingham, S.-A., Fornightly review - diet and the prevention of cancer. Br.     405 
Med. J. 1998, 317, 1636-1640. 406 
 407 
[2] Reddy, B.-S., Novel approaches to the prevention of colon cancer by nutritional 408 
manipulation and chemoprevention, Cancer Epidemiol. Biomark. Prev. 2000, 9, 239-247. 409 
 410 
[3] Kennedy, A.-R., Billings, P.-C., Wan, X.-S., Newberne, P.-M., Effects of Bowman-Birk in-411 
hibitor on rat colon carcinogenesis. Nutr. Cancer 2002, 43, 174-186. 412 
 413 
[4] Clemente, A., Domoney, C., Biological significance of polymorphism in plant protease 414 
inhibitors from the Bowman-Birk class. Curr. Prot. Pept. Sci. 2006, 7, 201-216. 415 
 416 
[5] Clemente, A., Domoney, C., in: Govil, J.N., Singh, V.K., Sharma, R.K. (Ed.), Recent 417 
Progress in Medicinal Plants (Vol 20) - Therapeutic properties of legume protease inhibitors from 418 
the Bowman-Birk class, SCI Tech Publishing LLC, Houston U.S.A. 2007, pp. 397-417.  419 
 420 
[6] Clemente, A., Jiménez, E., Marín-Manzano, M.-C., Rubio, L.-A., Functional Bowman-Birk 421 
inhibitors survive gastrointestinal digestion at the terminal ileum of cannulated pigs fed chickpea-422 
based diets. J. Sci. Food Agric. 2008, 88, 523-531. 423 
 424 
Page 18 of 36
Wiley-VCH
Molecular Nutrition and Food Research
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 18 
[7] Marín-Manzano, M.-C., Ruiz, R., Jimenez, E., Rubio, L.-A, Clemente, A., Anti-425 
carcinogenic Bowman-Birk inhibitors from soybean survive fermentation in active form using 426 
faecal inoculum and do not affect the microbiota composition. Br. J. Nutr. 2009, 101, 967-971.  427 
 428 
[8] Chen, P., Rose, J., Love, R., Wei, C.-H., Wang, B.-C., Reactive sites of an anticarcinogenic 429 
Bowman-Birk proteinase-inhibitor are similar to other trypsin-inhibitors. J. Biol. Chem. 1992, 267, 430 
1990-1994. 431 
 432 
[9]  Clemente, A., Vioque, J., Sanchez-Vioque, R., Pedroche, J., Bautista, J., Millán, F., 433 
Factors affecting the in vitro digestibility of chickpea albumins. J. Sci. Food Agric. 2000, 80, 79-434 
84. 435 
 436 
[10] Qi, R.-F., Song, Z.-W., Chi, C.-W., Structural features and molecular evolution of 437 
Bowman-Birk protease inhibitors and their potential application, Acta Biochim. Biophys. Sin. 2005, 438 
37, 283-292. 439 
 440 
[11] St Clair, W., Billings, P., Carew, J., Keller-McGandy, C., Newberne, P., Kennedy, A.-R., 441 
Suppression of dimethylhydrazine-induced carcinogenesis in mice by dietary addition of the 442 
Bowman-Birk protease inhibitor. Cancer Res. 1990, 50, 580-586. 443 
 444 
[12] Billings, P.-C., Brandon, D.-L., Habres, J.-M., Internalization of the Bowman-Birk protease 445 
inhibitor by intestinal epithelial cells. Eur. J. Cancer. 1991, 27, 903-908. 446 
 447 
[13] Fernandes, A.O., Banerji, A.P., Inhibition of benzopyrene-induced forestomach tumors by 448 
field bean protease inhibitor(s). Carcinogenesis 1995, 16, 1843-1846. 449 
Page 19 of 36
Wiley-VCH
Molecular Nutrition and Food Research
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 19 
[14] Ware, H.-W., Wan, S., Newberne, P., Kennedy, A.-R., Bowman-Birk concentrate reduces 450 
colon inflammation in mice with dextran sulphate sodium-induced ulcerative colitis, Digest. Dis. 451 
Sci. 1999, 44, 986-990. 452 
 453 
[15] Domoney, C., Welham, T., Ellis, N., Mozzanega, P., Turner, L., Three classes of proteinase 454 
inhibitor gene have distinct but overlapping patterns of expression in Pisum sativum plants, Plant 455 
Mol. Biol. 2002, 48, 319-329. 456 
 457 
[16] Sonnante, G., De Paolis, A., Pignone, D., Bowman-Birk inhibitors in Lens: identification 458 
and characterization of two paralogous gene classes in cultivated lentil and wild relatives, Theor. 459 
Appl. Genet. 2005, 110, 596-604. 460 
 461 
[17] Yavelow, J., Collins, M., Birk, Y., Troll, W., Kennedy, A.-R., Nanomolar concentrations of 462 
Bowman-Birk soybean protease inhibitor suppress X-ray induced transformation in vitro. Proc.  463 
Natl. Acad. Sci. USA, 1985, 82, 5395-5399. 464 
 465 
[18] Ware, J.-H., Wan, X.-S., Rubin, H., Schechter, N.-M., Kennedy, A.-R., Soybean Bowman-466 
Birk protease inhibitor is a highly effective inhibitor of human mast cell chymase. Arch. Biochem. 467 
Biophys. 1997,344, 133-138. 468 
 469 
[19] Clemente, A., MacKenzie, D.-A., Jeenes, D.-J., Domoney, C., The effect of variation 470 
within inhibitory domains on the activity of pea protease inhibitors from the Bowman-Birk class. 471 
Protein Express. Purif. 2004, 36, 106-114. 472 
 473 
Page 20 of 36
Wiley-VCH
Molecular Nutrition and Food Research
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 20 
[20] Clemente, A., Gee, J.-M., Johnson, I.-T., MacKenzie, D.-A., Domoney, C., Pea (Pisum 474 
sativum L.) protease inhibitors from the Bowman-Birk class influence the growth of human 475 
colorectal adenocarcinoma HT29 cells in vitro. J. Agric. Food Chem. 2005, 53, 8979-8986. 476 
 477 
[21] Domoney, C., Welham, T., Trypsin inhibitors in Pisum: variation in amount and pattern of 478 
accumulation in developing seed. Seed Sci. Res. 1992, 2, 147-154. 479 
 480 
[22] Copeland, R.-A., Lombardo, D., Giannaras, J., Dedicco, C.-P., Estimating Ki values for 481 
tight-binding inhibitors from dose-response plots. Bioorg. Med. Chem. Lett. 1995, 5, 1947-1952. 482 
 483 
[23] Schechter, I., Berger, A., On the size of the active site in proteases. I. Papain. Biochem. 484 
Biophys. Res. Commun. 1967, 27, 157-162. 485 
 486 
[24] Ferrasson, E., Quillien, L., Gueguen, J., Proteinase inhibitors from pea seeds: purification 487 
and characterization. J. Agric. Food Chem. 1997, 45, 127-131. 488 
 489 
[25] Ragg, E.-M., Galbusera, V., Scarafoni, A., Negri, A., Tedeschi, G., Consonni, A., Sessa, F., 490 
Duranti, M., Inhibitory properties and solution structure of a potent Bowman-Birk protease 491 
inhibitor from lentil (Lens culinaris L.) seeds. FEBS J. 2006, 273, 4024-4039. 492 
 493 
[26] Scarafoni, A., Consonni, A., Galbusera, V., Negri, A., Tedeschi, G., Rasmussen, P., Magni, 494 
C., Duranti, M., Identification and characterization of a Bowman-Birk inhibitor active towards 495 
trypsin but not chymotrypsin in Lupinus albus seeds. Phytochem. 2008, 69, 1820-1825. 496 
 497 
Page 21 of 36
Wiley-VCH
Molecular Nutrition and Food Research
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 21 
[27] Pan, M.-H., Ho, C.-T., Chemopreventive effects of natural dietary compounds on cancer 498 
development, Chem. Soc. Rev. 2008, 37, 2558-2574.  499 
 500 
[28] Lao, C.-D., Brenner, D.-E., Strategies for prevention of colorectal cancer: pharmaceutical 501 
and nutritional interventions. Curr. Treat. Options Oncol. 2004, 5, 417-426.   502 
 503 
[29] Billings, P.-C., Newberne, P., Kennedy, A.-R., Protease inhibitor suppression of colon and 504 
anal gland carcinogenesis induced by dimethylhydrazine. Carcinogenesis 1990, 11, 1083-1086. 505 
 506 
[30] Hernandez-Ledesma, B., Hsieh, C.-C., de Lumen, B.-O., Lunasin and Bowman-Birk 507 
protease inhibitor (BBI) in US commercial soy foods. Food Chem. 2009, 115, 574-580. 508 
 509 
[31] Kennedy, A.-R., The Bowman-Birk inhibitor from soybean as an anticancer agent. J. Clin. 510 
Am. Nutr. 1998, 1406S-1412S. 511 
 512 
[32] Rayas-Duarte, P., Bergeron, D., Nielsen, S.S., Screening of heat-stable trypsin inhibitors in 513 
dry beans and their partial purification from great northern beans (Phaseolus vulgaris) using 514 
anhydrotrypsin-Sepharose affinity chromatography. J. Agric. Food Chem. 1992, 40, 32-42. 515 
  516 
[33] Osman, M.-A, Reid, P.-M., Weber, C.-W., Thermal inactivation of tepary bean (Phaseolus 517 
acutifolius), soybean and lima bean protease inhibitors: effect of acidic and basic pH. Food Chem. 518 
2002, 78, 419-423. 519 
 520 
Page 22 of 36
Wiley-VCH
Molecular Nutrition and Food Research
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 22 
[34] Kennedy, A.R., Szuhaj, B.F., Newberne, P.M., Billings PC., Preparation and production of 521 
a cancer  chemopreventive agent., Bowman-Birk inhibitor concentrate. Nutr. Cancer 1993, 19, 522 
281-302. 523 
 524 
[35] Turk, B., Targeting proteases: successes, failures and future prospects. Nat. Rev. Drug 525 
Discov. 2006, 5, 785-799. 526 
 527 
[36] Darmoul, D., Gratio, V., Devaud, H., Lehy, T., Laburthe, M., Aberrant expression and 528 
activation of the thrombin receptor protease-activated receptor-1 induces cell proliferation and 529 
motility in human colon cancer cells. Am. J. Pathol. 2003, 162, 1503-1513. 530 
 531 
[37] Lee, S.-L., Dickson, R.-B., Lin C.-Y., Activation of hepatocyte growth factor and 532 
urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J. Biol. 533 
Chem. 2000, 275, 36720-36725. 534 
 535 
[38] Bhatt, A.-S., Takeuchi, T., Ylstra, B., Ginzinger, D., Albertson, D., Shuman, M.-A., Craik, 536 
C.-S., Quantitation of membrane type serine protease 1 (MT-SP1) in transformed and normal cells. 537 
Biol. Chem. 2006, 384, 257-266. 538 
 539 
[39] Bugge, T.-H., List, K., Szabo, R., Matriptase-dependent cell surface proteolysis in 540 
epithelial development and pathogenesis. Front. Biosci. 2007, 12, 5060-5070. 541 
 542 
[40] Yamasaki, Y., Satomi, S., Murai, N., Tsuzuki, S., Fushiki, T., Inhibition of membrane-type 543 
serine protease 1/matriptase by natural and synthetic protease inhibitors. J. Nutr. Sci. Vitaminol., 544 
2003, 49, 27-32. 545 
 546 
Page 23 of 36
Wiley-VCH
Molecular Nutrition and Food Research
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 23 
[41] Kisselev, A.-F., Callard, A., Goldberg, A.-L., Importance of the different proteolytic sites 547 
of the proteasome and the efficacy of inhibitors varies with the protein substrate. J. Biol. Chem. 548 
2006, 281, 8582-8590. 549 
 550 
[42] Chen, Y.-W., Huang, S.-C., Lin-Shiau, S.-Y., Lin, J.-K., Bowman-Birk inhibitor abates 551 
proteasome function and suppresses the proliferation of MCF7 breast cancer cells through 552 
accumulation of MAP kinase phosphatase-1. Carcinogenesis 2005, 26, 1296-1306 553 
 554 
 555 
FIGURE LEGENDS 556 
 557 
Figure 1. (a) SDS-PAGE under reducing conditions and (b) isoelectrofocusing (IEF) of 558 
unfractionated BBI from soybean (lanes 1 and 3, respectively). Molecular weight and pI markers 559 
are in lanes 2 and 4, respectively.  Arrows indicate the two major isoinhibitors of the mixture. 560 
 561 
Figure 2. (a) Fractionation of BBI from soybean by reverse-phase HPLC. (b) IEF of peaks 1 (lane 562 
1) and 2 (lane 2) that contain purified isoinhibitors. 563 
 564 
Figure 3. In-gel protease inhibitory activity analyses of soybean BBI. Zymogram Blue casein gels 565 
were treated with digestive enzymes, trypsin (T) or chymotrypsin (C); dark areas indicate where 566 
the enzyme has been inhibited (horizontal arrows). Lane 1: chemically inactivated soybean BBI; 567 
Lane 2: unfractionated BBI; Lane 3: purified IBBD2; Lane 4: purified IBB1.  Lanes 1 and 2 568 
contained 16 µg of protein, whereas lanes 3 and 4 contained 32 µg of protein. The direction of 569 
electrophoresis on non-denaturing gels is indicated, alongside the overall charge of the two 570 
isoinhibitors (vertical arrow). 571 
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 Figure 4. Dose-response effects of unfractionated soybean BBI on the growth of HT29 colon 572 
adenocarcinoma cells. Cells were treated with native soybean BBI (0-125 µM) for up to 96 h. 573 
Every point represents the mean of two independent experiments, each having four technical 574 
replicates; bars represent standard deviations. 575 
 576 
Figure 5.  Effects of native and chemically inactive BBI from soybean on the in vitro growth of a) 577 
HT29 human colorectal adenocarcinoma cells, and b) normal colon fibroblastic CCD-18Co cells. 578 
Growth media were supplemented with concentrations of BBI in the range 0-125 µM and cells 579 
harvested after a period of 96 hours. Data are means of at least three independent experiments, 580 
each having four technical replicates; bars represent standard deviations. Means not sharing 581 
superscript letters differ significantly (P<0.05; Bonferroni´s test). 582 
 583 
 Figure 6. Effects of the major soybean BBI isoinhibitors, IBBD2 and IBB1, on the in vitro growth 584 
of HT29 human colorectal adenocarcinoma cells. Growth media were supplemented with 585 
concentrations of BBI in the range 0-125 µM and cells harvested after a period of 96 hours. Data 586 
are means of at least three independent experiments, each having four technical replicates; bars 587 
represent standard deviations. Means not sharing superscript letters differ significantly (P<0.05; 588 
Bonferroni´s test). 589 
 590 
Figure 7. Cell cycle distribution pattern of HT29 cells after 24 h culture in the presence (31 and 62 591 
µM) or absence of soybean BBI. Cells were stained with propidium iodide and analysed by flow 592 
cytometry to measure fluorescence. The values given are the percentage of cells in every phase. 593 
Data are means of three independent experiments; bars represent standard deviations. 594 
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Table 1.  Identification of two major soybean BBI separated by reverse-phase HPLC 
 Chromatographic                                 Protein name                                          SWISS-Prot               Entry name            Sequence              Matched         Protein score  
peak identification                                                                                             accession number                                         coverage (%)         peptides 
                     1                            Bowman-Birk type proteinase inhibitor D-II             P01064                   IBBD2_SOYBN            96                             9                         205       
                     2                            Bowman-Birk proteinase inhibitor                             P01055                    IBB1_SOYBN              56                             5                         147               
Database searching was performed using the MASCOT database (http://www.matrixscience.com). 
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Table 2.  Amino acid sequence alignment of IBB1 and IBBD2 proteins 
1 - - - - - - - - 10 - - - - - - - - - 20 - - - - - - - - -30 - - - - - - - - - 40- - - - - - - - -50- - - - - - - - -60- - - - - - - - - 70 - - - - - - - - - 80 
Accession numbers are from Swiss_Prot database. Amino acid sequences of inhibitory domains are underlined.  P1-P1’ are the reactive peptide bond sites, in bold text. Either K or R at 
position P1 determines specificity for trypsin, whereas L determines specificity against chymotrypsin. The peptides that contributed to protein identification are indicated in italics. 
1 - - - - - - - - 10 - - - - - - - - - 20 - - - - - - - - -30 - - - - - - - - - 40- - - - - - - - -50- - - - - - - - -60- - - - - - - - - 70 - - - - - - - - - 80 
IBB1_SOYBN  (P01055)                         - - - - - - - -DDESSKPCCDQCACTKSNPPQCRCSDMRLNSCHSACKSCICALSYPAQCFCVDITDFCYEPCKPSEDDKEN 
 
IBBD2_SOYBN (P01064)        SDQSSSYDDDEYSKPCCDLCMCTRSMPPQCSCEDIRLNSCHSDCKSCMCTRSQPGQCRCLDTNDFCYKPCKSRDD- - - - 
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Table 3.  Inhibition constant (Ki) and specific inhibitory activity for trypsin (T) and chymotrypsin (C) of 
soybean Bowman-Birk isoinhibitors  
Soybean Bowman-Birk isoinhibitors                         Amino acid sequence of                                 Inhibition constant                          Specific inhibitory activity 
                                                                                            inhibitory domains                                                 (nM)                                               (IU/mg protein)  
                                                          Domain 1                           Domain 2                              T                      C                              T                          C  
              IBB1                                    CACTKSNPPQC                   CICALSYPAQC                29.8 ± 4.0          3.3 ± 1.0                2572 ± 122            5691 ± 365 
Specific activities and Ki values represent means ± SD from at least three independent determinations. P1-P1’ are the reactive peptide bond sites, marked in bold text. ND, not detected. 
 
            IBBD2                                   CMCTRSMPPQC                 CMCTRSQPGQC               14.8 ± 3.2              ND                     3710 ± 257                 ND 
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